Hyperfine rises as portable MRI contrast study begins

Shares of medical device maker Hyperfine HYPR.O rise 3.2% to $1.28 premarket

Co says it enrolled first patient in U.S. study testing contrast agents with its portable MRI system called Swoop

Study aims to see if gadolinium-based agents improve brain scans for conditions like tumors and inflammation, per co

About 70 patients to participate; results expected to support FDA submission for expanded use by end-2026 - HYPR

Contrast agents help doctors detect brain lesions and blood-brain barrier issues

Contrast agents are substances used in MRI scans to make certain tissues or abnormalities, like tumors or inflammation, more visible to doctors

As of last close, stock up ~11% over the past year